بررسی اعتبار و پایایی پرسشنامه MDS-UPDRS به زبان فارسی در بیماران مبتلا به پارکینسون مراجعه کننده به بیمارستان امام خمینی و روزبه تهران در سال 96:


۴ مهر ۱۳۹۶

: بیماری پارکینسون یک اختلال نورودژنراتیو پیشرونده است که دسترسی به معیار سنجش بیماری در درمانهای مختلف امری ضروری است. بنابراین هدف از این مطالعه بررسی اعتبار و پایایی پرسشنامه MDS-UPDRS به زبان فارسی در بیماران مبتلا به پارکینسون میباشد.

مواد و روش:  برای سنجش پایایی پرسشنامه، این مطالعه بر روی 63 بیمار مبتلا به پارکینسون و جهت سنجش روایی، پرسشنامه توسط 8 فرد متخصص مورد بررسی قرار گرفت و سپس روایی، پایایی و الفای کرونباخ و روایی سازه پرسشنامه مورد آنالیز قرار گرفت.

یافته ها: نتایج مطالعه حاضر نشان داد که نسخه فارسی 13 سوالی MDS-UPDRS دارای شاخص روایی محتوا 3/92 % و نسبت روایی محتوا برابر با 100% بود. همچنین مطالعه ما نشان داد که ضریب همبستگی اسپیرمن (پایایی) جهت بررسی پایایی آزمون برابر با 974/0 بود و آلفای کرونباخ پرسشنامه مورد استفاده برابر با 876/0 بود و همچنین میزان روایی سازه نیز قابل قبول بود.

نتیجه گیری: نتایج مطالعه حاضر نشان داد که نسخه فارسی 13 سوالی MDS-UPDRS قابلیت اطمینان داشته و برای بیماران مبتلا به پارکینسون قابل استفاده می باشد.

کلمات کلیدی: پارکینسون، پرسشنامه MDS-UPDRS، روایی و پایایی

مشخصات دانشجو:

نام:هادی کریمی مبین     رشته تحصيلي: پزشکی     مقطع:  دکترای حرفه ای                  گروه آموزشي: نورولوژی            پست الكترونيك دانشجو:   hadi.karimimobin@gmail.com

اساتيد راهنما و داور:

استاد راهنما : و دکتر عباس تفاخری اساتيد مشاور : دکتر لیلا صاحبی، دکتر وجیهه آقامولایی و  دکتر سکینه رنجی  اساتيد داور: دکتر غفار پور

زمان دفاع :

   روز   تاريخ  ساعت روز چهارشنبه 29 شهریور 96 ساعت 12 ظهر

مكان دفاع به آدرس: بیمارستان امام خمینی تهران، تالار پروفسور بریمانی

اطلاعات به زبان انگليسي

Title: The validity and reliability of MDS-UPDRS questionnaire in Persian language in patients with Parkinson's disease referring to Imam Khomeini and Roozbeh Hospitals in Tehran in 2017

Abstract:

Introduction: Parkinson's disease is a progressive neurodegenerative disorder, in which access to the criteria for assessing the disease in various treatments is essential. Therefore, the aim of this study was to evaluate the validity and reliability of the MDS-UPDRS questionnaire in Persian language in patients with Parkinson's disease.

Materials and Method: To assess the reliability of the questionnaire, 63 patients with Parkinson's disease were included in this study and the questionnaire was evaluated by 8 experts to assess the validity of the questionnaire. Then, Cronbach's validity, reliability, and structure validity of the questionnaire were analyzed.

Results: The results of this study showed that Persian version of MDS-UPDRS questionnaire had content validity index of 92.3% and content validity ratio of 100%. Our study also showed that the Spearman correlation coefficient (reliability) was 0.974, and Cronbach's alpha was 0.876 and the validity of the structure was also acceptable.

Conclusion: The results of this study showed that Persian version 13 questions of MDS-UPDRS are reliable and can be used for patients with Parkinson's disease.

Keywords: Parkinson, MDS-UPDRS, Validity and Reliability

فهرست منابع و ماخذ فارسي و لاتين:

 

1.      Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology. 2009;72(21 suppl 4):S1-S136.

2.      Mehta P, Kifley A, Wang JJ, Rochtchina E, Mitchell P, Sue CM: Population prevalence and incidence of Parkinson’s disease in an Australian community. Intern Med J 2007; 37:812–814.

3.      de Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurol. 2006;5(6):525-535.

4.      Scottish Intercollegiate Guidelines Network. Diagnosis and Pharmacological Management of Parkinson’s disease: A National Clinical Guideline. Edinburgh: Scottish Intercollegiate Guidelines Network; January 2010. http://www.sign.ac.uk/pdf/sign113.pdf. Accessed March 8, 2011.

5.      Opara J. Current possibilities of evaluation of quality of life in Parkinson disease. Neurol Neurochir Pol.2003;37 Suppl 5:241-50.[Article in Polish].

6.      Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson’s disease: an evidencebased review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2002;58(1):11-17.

7.      The National Collaborating Centre for Chronic Conditions. Parkinson’s Disease: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care. London: Royal College of Physicians; 2006. http://www.nice.org.uk/nicemedia /live/10984/30087/30087.pdf. Accessed March 8, 2011.

8.      Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidencebased review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):983-995.

9.      Suchowersky O, Gronseth G, Perlmutter J, Reich S, Zesiewicz T, Weiner WJ. Practice parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology published correction appears in Neurology. 2006;67(2):299]. Neurology. 2006;66(7):976-982.]

10.  JOHN D G, D. ROXANNE R, KARL C, Parkinson Disease: An Update. American Family Physician. Volume 87, Number 4 , February 15, 2013

11.  J. Kulisevskya, M.R. Luquinb, J.M. Arbeloc, J.A. Burguerad, F. Carrillo e, A. Castrof, J. Chacóng, P.J. García-Ruizh, E. Lezcanoi, P. Mire, J.C. Martinez-Castrilloj, I. Martínez-Torresd, V. Puentek, A. Sesarf, F. Valldeoriola-Serral, R. Ya˜nezm. Advanced Parkinson’s disease: Clinical characteristics and treatment (part 1). Neurología. 2013;28(8):503—521

12.  Christopher G. Goetz, Barbara C. Tilley, Stephanie R. Shaftman, Glenn T. Stebbins, Stanley Fahn, Pablo Martinez-Martin, Werner Poewe, Cristina Sampaio, Matthew B. Stern, Richard Dodel, Bruno Dubois, Robert Holloway, Joseph Jankovic, Jaime Kulisevsky, Anthony E. Lang, Andrew Lees,  Sue Leurgans, Peter A. LeWitt, David Nyenhuis, C. Warren Olanow, Olivier Rascol, Anette Schrag, Jeanne A. Teresi, Jacobus J. van Hilten, and Nancy LaPelle. Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): Scale Presentation and Clinimetric Testing Results. Movement Disorders, Vol. 23, No. 15, 2008: 2129-2170.

13.  Angelo Antonini • Giovanni Abbruzzese • Luigi Ferini-Strambi • Barbara Tilley • Jing Huang • Glenn T. Stebbins et al. Validation of the Italian version of the Movement Disorder Society—Unified Parkinson’s Disease Rating Scale. Neurol Sci (2013) 34:683–687.

14.  David A. Gallagher, MRCP,1 Christopher G. Goetz, MD,2 Glenn Stebbins, PhD,2 Andrew J. Lees, MD, FRCP, FMedSci, and Anette Schrag, MD, PhD, FRCP. Validation of the MDS-UPDRS Part I for Nonmotor Symptoms in Parkinson’s Disease. Movement Disorders, Vol. 27, No. 1, 2012.

15.  Hauser RA, Grosset DG. [(123) I]FP-CIT (DaTscan) SPECT Brain Imaging in Patients with Suspected Parkinsonian Syndromes. J Neuroimaging. 2011 Mar 16. [Medline].

16.  Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol. 2011 Jun. 26 Suppl 1:S1-58. [Medline].

17.  Anderson P. More Evidence Links Pesticides, Solvents, With Parkinson's. Medscape Medical News. Available at http://www.medscape.com/viewarticle/804834. Accessed: June 11, 2013.

18.  Pezzoli G, Cereda E. Exposure to pesticides or solvents and risk of Parkinson disease. Neurology. 2013 May 28. 80(22):2035-41. [Medline].

19.  Liu R, Guo X, Park Y, Huang X, Sinha R, Freedman ND, et al. Caffeine Intake, Smoking, and Risk of Parkinson Disease in Men and Women. Am J Epidemiol. 2012 Apr 13. [Medline].

20.  Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology. 1985 Jul. 35(7):949-56. [Medline].

21.  Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R, et al. Parkinson disease in twins: an etiologic study. JAMA. 1999 Jan 27. 281(4):341-6. [Medline].

22.  Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997 Jun 27. 276(5321):2045-7. [Medline].

23.  Krüger R, Kuhn W, Müller T, Woitalla D, Graeber M, Kösel S, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet. 1998 Feb. 18(2):106-8. [Medline].

24.  Bekris LM, Mata IF, Zabetian CP. The genetics of Parkinson disease. J Geriatr Psychiatry Neurol. 2010 Dec. 23(4):228-42. [Medline][Full Text].

25.  Alcalay RN, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Ross BM, et al. Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study. Arch Neurol. 2010 Sep. 67(9):1116-22. [Medline].

26.  Samanta J, Hauser RA. Duodenal levodopa infusion for the treatment of Parkinson's disease. Expert Opin Pharmacother. 2007 Apr. 8(5):657-64. [Medline].

27.  Vekrellis K, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis L. Pathological roles of a-synuclein in neurological disorders. Lancet Neurol. 2011 Nov. 10(11):1015-25. [Medline].

28.  Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med. 2008 May. 14(5):504-6. [Medline].

29.  Dalvin LA, Damento GM, Yawn BP, Abbott BA, Hodge DO, Pulido JS. Parkinson Disease and Melanoma: Confirming and Reexamining an Association. Mayo Clin Proc. 2017 Jul. 92 (7):1070-1079. [Medline].

30.  Mulcahy, N. Melanoma, Parkinson's: See One, Be Aware of the Other. Medscape Medical News. Available at http://www.medscape.com/viewarticle/883195. July 19, 2017; Accessed: July 26, 2017.

31.  Constantinescu R, Elm J, Auinger P, Sharma S, Augustine EF, Khadim L, et al. Malignant melanoma in early-treated Parkinson's disease: the NET-PD trial. Mov Disord. 2014 Feb. 29 (2):263-5. [Medline].

32.  Muangpaisan W, Mathews A, Hori H, Seidel D. A systematic review of the worldwide prevalence and incidence of Parkinson's disease. J Med Assoc Thai. 2011 Jun. 94(6):749-55. [Medline].

33.  Grimes DA, Lang AE. Treatment of early Parkinsons disease. Can J Neurol Sci. 1999 Aug. 26 Suppl 2:S39-44. [Medline].

34.  Thobois S, Delamarre-Damier F, Derkinderen P. Treatment of motor dysfunction in Parkinsons disease: an overview. Clin Neurol Neurosurg. 2005 Jun. 107(4):269-81. [Medline].

35.  Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner WJ. Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006 Apr 11. 66(7):968-75. [Medline].

36.  National Collaborating Centre for Chronic Conditions. Parkinson's disease: National clinical guideline for diagnosis and management in primary and secondary care. London, UK: Royal College of Physicians; 2006.

37.  Hughes S. Consider Nonmotor Symptoms for Diagnosis of Parkinson's? Medscape Medical News. January 18, 2013. Available at http://www.medscape.com/viewarticle/777874. Accessed: January 22, 2013.

38.  Khoo TK, Yarnall AJ, Duncan GW, Coleman S, O'Brien JT, Brooks DJ, et al. The spectrum of nonmotor symptoms in early Parkinson disease. Neurology. 2013 Jan 15. 80(3):276-81. [Medline].

39.  Simuni T, Sethi K. Nonmotor manifestations of Parkinson's disease. Ann Neurol. 2008 Dec. 64 Suppl 2:S65-80. [Medline].

40.  Sato Y, Iwamoto J, Honda Y. Vitamin D Deficiency-Induced Vertebral Fractures May Cause Stooped Posture in Parkinson Disease. Am J Phys Med Rehabil. 2011 Jan 5. [Medline].

41.  Brin MF, Velickovic M, Remig LO. Dysphonia due to Parkinson's disease; pharmacological, surgical, and behavioral management perspectives. Vocal Rehabilitation in Medical Speech-Language Pathology. Austin: Pro-Ed; 2004. 209-69.

42.  Perez KS, Ramig LO, Smith ME, Dromey C. The Parkinson larynx: tremor and videostroboscopic findings. J Voice. 1996 Dec. 10(4):354-61. [Medline].

43.  Ray Chaudhuri K, Rojo JM, Schapira AH, Brooks DJ, Stocchi F, Odin P, et al. A proposal for a comprehensive grading of Parkinson's disease severity combining motor and non-motor assessments: meeting an unmet need. PLoS One. 2013. 8(2):e57221. [Medline][Full Text].

44.  Johnson K. Nonmotor PD Symptoms Bolster Disease Severity Assessment. Medscape [serial online]. Available at http://www.medscape.com/viewarticle/812182. Accessed: October 13, 2013.

45.  Hoops S, Nazem S, Siderowf AD, Duda JE, Xie SX, Stern MB. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology. 2009 Nov 24. 73(21):1738-45. [Medline][Full Text].

46.  Weintraub D, Comella CL, Horn S. Parkinson's disease--Part 3: Neuropsychiatric symptoms. Am J Manag Care. 2008 Mar. 14(2 Suppl):S59-69. [Medline].

47.  Reid WG, Hely MA, Morris JG, Loy C, Halliday GM. Dementia in Parkinson's disease: a 20-year neuropsychological study (Sydney Multicentre Study). J Neurol Neurosurg Psychiatry. 2011 Sep. 82(9):1033-7. [Medline].

48.  Parkinson's Tied to Higher Risk of Osteoporosis and Osteopenia. Medscape. Apr 3 2014. [Full Text].

49.  Torsney KM, Noyce AJ, Doherty KM, et al. Bone health in Parkinson's disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2014 Mar 21. [Medline].

50.  Tolosa E, Gaig C, Santamaría J, Compta Y. Diagnosis and the premotor phase of Parkinson disease. Neurology. 2009 Feb 17. 72(7 Suppl):S12-20. [Medline].

51.  King J. New contrast agent enables earlier diagnosis in Parkinson's. Medscape Medical News. June 18, 2013. [Full Text].

52.  Seibyl J, Jennings D, Grachev I, Coffey C, Marek K. Accuracy of DaTscan™ (ioflupane I 123 injection) in diagnosis of early parkinsonian syndromes (PS) [abstract 191]. Presented at: 2013 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI); June 10, 2013; Vancouver, British Columbia, Canada.

53.  Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004 Oct. 318(1):121-34. [Medline].

54.  Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, et al. Association of Cerebrospinal Fluid ß-Amyloid 1-42, T-tau, P-tau181, and a-Synuclein Levels With Clinical Features of Drug-Naive Patients With Early Parkinson Disease. JAMA Neurol. 2013 Aug 26. [Medline].

55.  Jeffrey S. Biomarkers for Parkinson's Diagnostic, Prognostic. Medscape [serial online]. Available at http://www.medscape.com/viewarticle/810262. Accessed: September 9, 2013.

56.  Grosset D, Taurah L, Burn DJ, MacMahon D, Forbes A, Turner K, et al. A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis. J Neurol Neurosurg Psychiatry. 2007 May. 78(5):465-9. [Medline][Full Text].

57.  Caslake R, Macleod A, Ives N, Stowe R, Counsell C. Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease. Cochrane Database Syst Rev. 2009. (4):CD006661. [Medline].

58.  Antonini A, Cilia R. Behavioural adverse effects of dopaminergic treatments in Parkinson's disease: incidence, neurobiological basis, management and prevention. Drug Saf. 2009. 32(6):475-88. [Medline].

59.  Bayulkem K, Lopez G. Clinical approach to nonmotor sensory fluctuations in Parkinson's disease. J Neurol Sci. 2011 Nov 15. 310(1-2):82-5. [Medline].

60.  Miyasaki JM, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K, et al. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006 Apr 11. 66(7):996-1002. [Medline].

61.  [Guideline] Zesiewicz TA, Sullivan KL, Arnulf I, et al. Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2010 Mar 16. 74(11):924-31. [Medline].

62.  Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol. 2010 Jul. 68(1):18-27. [Medline].

63.  Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol. 2006 Dec. 63(12):1756-60. [Medline].

64.  Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med. 2000 May 18. 342(20):1484-91. [Medline].

65.  Constantinescu R, Romer M, McDermott MP, Kamp C, Kieburtz K. Impact of pramipexole on the onset of levodopa-related dyskinesias. Mov Disord. 2007 Jul 15. 22(9):1317-9. [Medline].

66.  Thomas A, Bonanni L, Gambi F, Di Iorio A, Onofrj M. Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol. Sep 2010. 68(3):400-4.

67.  Weintraub D, Sohr M, Potenza MN, Siderowf AD, Stacy M, Voon V, et al. Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol. 2010 Dec. 68(6):963-8. [Medline].

68.  Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014 Feb. 13(2):141-9. [Medline].

69.  Schapira AH, Fox SH, Hauser RA, Jankovic J, Jost WH, Kenney C, et al. Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. JAMA Neurol. 2017 Feb 1. 74 (2):216-224. [Medline].

70.  Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt M, Chirilineau D, et al. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations. Mov Disord. 2014 Feb. 29 (2):229-37. [Medline][Full Text].

71.  Schapira AH, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, et al. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology. 2011 Aug 23. 77(8):767-74. [Medline].

72.  Ory-Magne F, Corvol JC, Azulay JP, et al, on behalf of the NS-Park CIC Network. Withdrawing amantadine in dyskinetic patients with Parkinson disease: The AMANDYSK trial. Neurology. 2013 Dec 26. [Medline].

73.  Brooks M. Amantadine has lasting benefit on levodopa-induced dyskinesia. Medscape Medical News. January 8, 2014. [Full Text].

74.  Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N Engl J Med. 1993 Jan 21. 328(3):176-83. [Medline].

75.  Shults CW. Effect of selegiline (deprenyl) on the progression of disability in early Parkinson's disease. Parkinson Study Group. Acta Neurol Scand Suppl. 1993. 146:36-42. [Medline].

76.  Palhagen S, Heinonen E, Hagglund J, Kaugesaar T, Maki-Ikola O, Palm R. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology. 2006 Apr 25. 66(8):1200-6. [Medline].

77.  Tatton WG, Greenwood CE. Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res. 1991 Dec. 30(4):666-72. [Medline].

78.  Olanow C, Rascol O. Early Rasagaline treatment slows UPDRS decline in the ADAGIO delayed start study. Poster work in progress (WIP-11). 12th Congress of European Federation of Neurological Societies. Sept 23, 2008.

79.  Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009 Sep 24. 361(13):1268-78. [Medline].

80.  A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002 Dec. 59(12):1937-43. [Medline].

81.  Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, Fitzer-Attas CJ. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord. 2009 Mar 15. 24(4):564-73. [Medline].

82.  A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol. 2004 Apr. 61(4):561-6. [Medline].

83.  Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004 Dec 9. 351(24):2498-508. [Medline].

84.  Parkkinen L, O'Sullivan SS, Kuoppamäki M, Collins C, Kallis C, Holton JL, et al. Does levodopa accelerate the pathologic process in Parkinson disease brain?. Neurology. 2011 Oct 11. 77(15):1420-6. [Medline].

85.  Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA. 2002 Apr 3. 287(13):1653-61. [Medline].

86.  Schapira AH, Olanow CW. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA. 2004 Jan 21. 291(3):358-64. [Medline].

87.  Suchowersky O, Gronseth G, Perlmutter J, Reich S, Zesiewicz T, Weiner WJ. Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006 Apr 11. 66(7):976-82. [Medline].

88.  Shemisa K, Hass CJ, Foote KD, Okun MS, Wu SS, Jacobson CE 4th, et al. Unilateral deep brain stimulation surgery in Parkinson's disease improves ipsilateral symptoms regardless of laterality. Parkinsonism Relat Disord. 2011 Dec. 17(10):745-8. [Medline].

89.  Weaver FM, Follett K, Stern M, Hur K, Harris C, Marks WJ Jr. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA. 2009 Jan 7. 301(1):63-73. [Medline][Full Text].

90.  Follett KA, Weaver FM, Stern M, Hur K, Harris CL, Luo P, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med. 2010 Jun 3. 362(22):2077-91. [Medline].

91.  Brooks M. Neurostimulation has benefits in early Parkinson's disease. Medscape Medical News. February 15, 2013. [Full Text].

92.  Schuepbach WM, Rau J, et al, for the EARLYSTIM Study Group. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med. 2013 Feb 14. 368(7):610-22. [Medline].

93.  Foltynie T, Zrinzo L, Martinez-Torres I, Tripoliti E, Petersen E, Holl E, et al. MRI-guided STN DBS in Parkinson's disease without microelectrode recording: efficacy and safety. J Neurol Neurosurg Psychiatry. 2011 Apr. 82(4):358-63. [Medline].

94.  Moreau C, Delval A, Defebvre L, Dujardin K, Duhamel A, Petyt G, et al. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol. 2012 Jul. 11(7):589-596. [Medline].

95.  Castrioto A, Lozano AM, Poon YY, Lang AE, Fallis M, Moro E. Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Arch Neurol. 2011 Dec. 68(12):1550-6. [Medline].

96.  Oshima H, Katayama Y, Morishita T, Sumi K, Otaka T, Kobayashi K, et al. Subthalamic nucleus stimulation for attenuation of pain related to Parkinson disease. J Neurosurg. 2012 Jan. 116(1):99-106. [Medline].

97.  Kim HJ, Jeon BS, Paek SH. Effect of deep brain stimulation on pain in Parkinson disease. J Neurol Sci. 2011 Nov 15. 310(1-2):251-5. [Medline].

98.  Kim HJ, Jeon BS, Lee JY, Paek SH, Kim DG. The benefit of subthalamic deep brain stimulation for pain in Parkinson disease: a 2-year follow-up study. Neurosurgery. 2012 Jan. 70(1):18-23; discussion 23-4. [Medline].

99.  Broen M, Duits A, Visser-Vandewalle V, Temel Y, Winogrodzka A. Impulse control and related disorders in Parkinson's disease patients treated with bilateral subthalamic nucleus stimulation: a review. Parkinsonism Relat Disord. 2011 Jul. 17(6):413-7. [Medline].

100.                      Svennilson E, Torvik A, Lowe R, Leksell L. Treatment of parkinsonism by stereotatic thermolesions in the pallidal region. A clinical evaluation of 81 cases. Acta Psychiatr Scand. 1960. 35:358-77.

101.                      Laitinen LV, Bergenheim AT, Hariz MI. Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. J Neurosurg. 1992 Jan. 76(1):53-61. [Medline].

102.                      Lang AE, Widner H. Deep brain stimulation for Parkinson's disease: patient selection and evaluation. Mov Disord. 2002. 17 Suppl 3:S94-101. [Medline].

103.                      Okun MS, Fernandez HH, Pedraza O, Misra M, Lyons KE, Pahwa R. Development and initial validation of a screening tool for Parkinson disease surgical candidates. Neurology. 2004 Jul 13. 63(1):161-3. [Medline].

104.                      Olanow CW, Kordower JH, Lang AE, Obeso JA. Dopaminergic transplantation for Parkinson's disease: current status and future prospects. Ann Neurol. 2009 Nov. 66(5):591-6. [Medline].

105.                      Silberstein P, Bittar RG, Boyle R, Cook R, Coyne T, O'Sullivan D. Deep brain stimulation for Parkinson's disease: Australian referral guidelines. J Clin Neurosci. 2009 Aug. 16(8):1001-8. [Medline].

106.                      Stover NP, Watts RL. Spheramine for treatment of Parkinson's disease. Neurotherapeutics. 2008 Apr. 5(2):252-9. [Medline].

107.                      Farag ES, Vinters HV, Bronstein J. Pathologic findings in retinal pigment epithelial cell implantation for Parkinson disease. Neurology. 2009 Oct 6. 73(14):1095-102. [Medline][Full Text].

108.                      Witt J, Marks WJ Jr. An update on gene therapy in Parkinson's disease. Curr Neurol Neurosci Rep. 2011 Aug. 11(4):362-70. [Medline].

109.                      Lewitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, et al. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol. 2011 Apr. 10(4):309-19. [Medline].

110.                      Miyasaki JM, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K, et al. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006 Apr 11. 66(7):996-1002. [Medline].

111.                      Frisina PG, Borod JC, Foldi NS, Tenenbaum HR. Depression in Parkinson''s disease: Health risks, etiology, and treatment options. Neuropsychiatr Dis Treat. 2008 Feb. 4(1):81-91. [Medline][Full Text].

112.                      Barbas NR. Cognitive, affective, and psychiatric features of Parkinson's disease. Clin Geriatr Med. 2006 Nov. 22(4):773-96, v-vi. [Medline].

113.                      Truong DD, Bhidayasiri R, Wolters E. Management of non-motor symptoms in advanced Parkinson disease. J Neurol Sci. 2008 Mar 15. 266(1-2):216-28. [Medline].

114.                      Ziemssen T, Reichmann H. Non-motor dysfunction in Parkinson's disease. Parkinsonism Relat Disord. 2007 Aug. 13(6):323-32.

115.                      Forjaz MJ1, Ayala A2, Testa CM3, Bain PG4, Elble R5, Haubenberger D6, et al. Proposing a Parkinson's disease-specific tremor scale from the MDS-UPDRS. Mov Disord. 2015 Jul;30(8):1139-43. doi: 10.1002/mds.26271. Epub 2015 Jun 11.

116.                      Goetz CG1, Tilley BCShaftman SRStebbins GTFahn SMartinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 Nov 15;23(15):2129-70. doi: 10.1002/mds.22340.

117.                      Amir Abdolahi, Nicholas Scoglio, Annie Killoran, Ray Dorsey, Kevin M. Biglan. Potential reliability and validity of a modified version of the Unified Parkinson’s DiseaseRating Scale that could be administered remotely. Parkinsonism Relat Disord. Author manuscript; available in PMC 2014 Feb 1. Published in final edited form as: Parkinsonism Relat Disord. 2013 Feb; 19(2): 218–221.

118.                      Martinez-Martin P1, Rodriguez-Blazquez CAlvarez-Sanchez MArakaki TBergareche-Yarza AChade A, et al. Expanded and independent validation of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). J Neurol. 2013 Jan;260(1):228-36. doi: 10.1007/s00415-012-6624-1. Epub 2012 Aug 5



منبع: معاونت پژوهشي دانشکده پزشکي